What Xilio Therapeutics Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 1 |
| Sells | 0 | 2 |
| Total trades | 0 | 7 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 90,250 |
| Disposed | 0 | 8,856 |
| Net activity | +0 | +81,394 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Shannon James Samuel | Director | Mar 26 | Open-market buy · P | +5,000 | $8.79 | +$44K | 10,000 |
| Frankenfield Christopher James | Chief Financial Officer | Jan 02 | Open-market sale · S | −7,030 | $0.64 | −$4.52K | 24,766 |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Jan 02 | Open-market sale · S | −1,826 | $0.64 | −$1.17K | 6,371 |
| Frankenfield Christopher James | Chief Financial Officer | Jan 01 | Exercise / conversion · M | +19,375 | — | — | 31,796 |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Jan 01 | Exercise / conversion · M | +5,000 | — | — | 8,197 |
| Russo Rene | PRESIDENT AND CEO | Jan 01 | Exercise / conversion · M | +44,250 | — | — | 325,422 |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | Jan 01 | Exercise / conversion · M | +16,625 | — | — | 33,250 |
| Shannon James Samuel | Director | Jun 17 | Open-market buy · P | +25,000 | $0.69 | +$17.2K | 70,000 |
| Russo Rene | PRESIDENT AND CEO | Jun 16 | Open-market buy · P | +36,289 | $0.68 | +$24.7K | 281,172 |
| Shannon James Samuel | Director | Jun 16 | Open-market buy · P | +45,000 | $0.69 | +$30.9K | 45,000 |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Jan 02 | Open-market sale · S | −1,803 | $0.98 | −$1.77K | 3,197 |
| Frankenfield Christopher James | Chief Financial Officer | Jan 02 | Open-market sale · S | −6,954 | $0.98 | −$6.84K | 12,421 |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Jan 01 | Exercise / conversion · M | +5,000 | — | — | 5,000 |
| Frankenfield Christopher James | Chief Financial Officer | Jan 01 | Exercise / conversion · M | +19,375 | — | — | 19,375 |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | Jan 01 | Exercise / conversion · M | +16,625 | — | — | 16,625 |
| Gilead SCIENCES, Inc. | 10% owner | Dec 18 | Open-market buy · P | +1,759,978 | $1.04 | +$1.83M | 9,105,451 |
| Gilead SCIENCES, Inc. | 10% owner | Apr 02 | Open-market buy · P | +485,250 | $0.76 | +$369K | 7,345,473 |
| Atlas Venture Fund XI, L.p. | 10% owner | Feb 08 | Open-market sale · S | −267 | $0.64 | −$171 | 734,546 |
| Atlas Venture Fund XI, L.p. | 10% owner | Feb 08 | Open-market sale · S | −733 | $0.64 | −$469 | 2,019,563 |
| Atlas Venture Fund XI, L.p. | 10% owner | Jan 12 | Open-market sale · S | −560 | $0.83 | −$465 | 734,813 |
Loading...
